Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Tissue adhesive internal use

PMA Number: P220024 · 2026-01-14

ApplicantAdvanced Medical Solutions Limited
Decision Date2026-01-14
PMA NumberP220024
Product CodePLJ
Device ClassClass 3
Medical SpecialtyG
Regulation Number21 CFR 8
Advisory CommitteeSU

Device Summary

Tissue adhesive internal use is the device name listed in this FDA 510(k) record. The listed applicant is Advanced Medical Solutions Limited. It received FDA 510(k) clearance on 2026-01-14. The device is classified under product code PLJ. It was reviewed by the SU advisory panel.

Frequently Asked Questions

What is the Tissue adhesive internal use?

Tissue adhesive internal use is a medical device that received FDA 510(k) clearance on 2026-01-14. The listed applicant is Advanced Medical Solutions Limited.

When did Tissue adhesive internal use receive FDA 510(k) clearance?

The clearance date for Tissue adhesive internal use can be found in the official FDA records.

Who is the listed applicant for Tissue adhesive internal use?

The FDA 510(k) record lists Advanced Medical Solutions Limited as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Tissue adhesive internal use?

The FDA product code for Tissue adhesive internal use is PLJ.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑